LuciNira — Niraparib 100 mg, 30 pcs, Lucius

LuciNira — Niraparib Tablets 100 mg, 30 Tablets

Product code: 498

23244₴ 25300₴ -8% On order · from 10 days

Analogues

LuciNira Niranib
1
Active ingredient
Dosage
100 mg
Dosage form Tablets
Tablets per pack 30

LuciNira is an advanced targeted antineoplastic agent belonging to the poly (ADP-ribose) polymerase (PARP) inhibitor class, indicated for maintenance treatment of epithelial ovarian, fallopian tube, and primary peritoneal cancer. The active pharmaceutical ingredient is niraparib at a strength of 100 mg supplied as film-coated oral tablets (Niraparib Tablets 100 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Niraparib is a potent, selective oral inhibitor of PARP1 and PARP2 enzymes. Its mechanism of action relies on synthetic lethality: tumor cells with homologous recombination deficiency (HRD), including BRCA1/2 mutations, are highly vulnerable to PARP inhibition because blocking this enzyme prevents the repair of single-strand DNA breaks, leading to double-strand breaks, cell cycle arrest, and cancer cell death. Niraparib is utilized to maintain remission following platinum-based chemotherapy regardless of BRCA status or homologous recombination deficiency status, as well as for treating recurrent disease.

Supplied in a package containing 30 tablets of 100 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciNira 100 mg:

  • ✅ PARP1 & PARP2 Inhibitor: Highly effective suppression of tumor DNA repair enzymes.
  • ✅ BRCA/HRD-Independent Efficacy: Demonstrated clinical benefit in maintenance therapy for both BRCA-mutated and wild-type patients.
  • ✅ Sustained Remission: Significant prolongation of progression-free survival following responses to platinum chemotherapy.
  • ✅ Convenient Oral Dosing: Taken orally once daily regardless of food intake.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Zejula).

LuciNira is supplied as film-coated tablets for oral administration.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Niraparib (as niraparib tosylate monohydrate) — 100 mg.
  • Excipients: Lactose monohydrate, microcrystalline cellulose, colloidal anhydrous silica, magnesium stearate, crospovidone. Coating: hypromellose, titanium dioxide, macrogol, colorants.

Packaging and Presentation: Film-coated tablets, 100 mg strength. Each package contains 30 tablets along with prescribing information. Labeled with LuciNira (Niraparib Tablets 100 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Niraparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, specifically PARP1 and PARP2, which play a vital role in single-strand DNA break repair. PARP inhibition by niraparib results in the formation of cytotoxic double-strand DNA breaks during DNA replication. In tumor cells with homologous recombination deficiency (e.g., BRCA1/2 mutations), these double-strand breaks cannot be accurately repaired, resulting in synthetic lethality and tumor cell apoptosis.

Pharmacokinetics:

  • Absorption: Following oral administration, niraparib is rapidly and almost completely absorbed. Absolute bioavailability is approximately 73%. Peak plasma concentration (Tmax) is achieved within approximately 3 hours. Food intake has no clinically significant effect on absorption.
  • Distribution: Human plasma protein binding is approximately 83% (primarily bound to albumin). High volume of distribution indicates extensive tissue penetration.
  • Metabolism: Metabolized primarily via carboxylesterase-mediated conversion into inactive metabolites.
  • Elimination: Excreted predominantly renally (approx. 40% as metabolites) and via feces (approx. 47%). Terminal elimination half-life (T1/2) averages 36 to 48 hours.

LuciNira is indicated in adult patients for:

  • Ovarian, Fallopian Tube, and Primary Peritoneal Cancer: As maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
  • Recurrent Ovarian Cancer: Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

LuciNira is administered orally once daily every day at approximately the same time (preferably at bedtime to mitigate nausea).

Dosing Regimen:
The recommended starting dose for patients with a baseline body weight of less than 77 kg or baseline platelet count of less than 150,000/mcL is 200 mg (two 100 mg tablets) once daily. For patients with a baseline body weight of 77 kg or greater and baseline platelet count of 150,000/mcL or greater, the recommended dose is 300 mg (three 100 mg tablets) once daily.

Administration Guidelines:
Tablets should be swallowed whole with water; do not break, crush, or chew. Food intake does not affect bioavailability. If a dose is missed, take the next scheduled dose at the usual time the following day (do not double doses).

Administration of LuciNira is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to niraparib or any excipient (including lactose intolerance).
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women due to significant embryotoxic risks.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic or Renal Impairment: Pronounced liver or kidney dysfunction (per clinical guidelines).

Niraparib exhibits a low potential for pharmacokinetic drug interactions:

  • CYP450 Enzymes: Niraparib is not a substrate, inducer, or major inhibitor of cytochrome P450 enzymes, minimizing hepatic drug-drug interaction risks.
  • Transporters (P-gp, BCRP): Niraparib and its major metabolite may exert minimal effects on transporter proteins, though clinically significant interactions with co-administered drugs are generally absent.
  • Myelosuppressive Agents: Concurrent administration with other bone marrow-suppressive antineoplastic therapies may exacerbate hematologic toxicity.

Pregnancy:
LuciNira is contraindicated during pregnancy. Based on its mechanism of action, niraparib may cause fetal harm when administered to pregnant women. Females of reproductive potential must utilize effective contraception during treatment and for at least 6 months following the final dose.

Lactation:
Excretion of niraparib into human breast milk is unstudied. Breastfeeding must be discontinued during treatment and for 1 month post-therapy.

The most frequent and clinically significant adverse reactions include:

  • Hematologic Toxicity (Very Common): Thrombocytopenia, anemia, neutropenia, leukopenia. Weekly complete blood counts are required for the first month, followed by monthly monitoring for the subsequent year of therapy.
  • Gastrointestinal Tract: Nausea, constipation, vomiting, abdominal pain, diarrhea, dry mouth, dyspepsia.
  • Cardiovascular System: Arterial hypertension, tachycardia (regular blood pressure and heart rate monitoring required).
  • General Disorders: Fatigue, asthenia, insomnia, headache, dizziness, decreased appetite.
  • Serious Complications: Rare reports of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).

Symptoms:
Specific acute overdose symptoms of niraparib are unestablished. Anticipated manifestations include exacerbated adverse reactions (primarily hematologic toxicity and gastrointestinal disturbances).

Treatment:
No specific antidote exists. In case of overdose, discontinue niraparib, monitor blood counts closely, and provide supportive and symptomatic care.

Storage Requirements for LuciNira 100 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Don't use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciNira 100 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics and Niraparib Tablets 100 mg.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 14.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00